Companies / United Arab Emirates
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Novartis Launches Exjade
September 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Sufferers of a rare genetic disorder in the UAE will take heart with the news that Swiss pharmaceutical firm Novartis is about to launch its long awaited drug Exjade (deferasirox) in the country. Exjade works by removing excess iron from thalassaemia patients. The blood disorder - which obstructs the body's production of haemoglobin - affects between 3-10% of the population in the country